UroGen Pharma   Report issue

For profit Phase 2 Phase 3
Founded: New York NY United States (2004)

Organization Overview

First Clinical Trial
2014
NCT02307487
First Marketed Drug
2020
mitomycin (mutamycin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

iklein@urogen.com | UroGen-Parma LTD | UroGen Pharma | UROGEN PHARMA | UroGen Pharma Ltd.